Home » BWI News » 2010 » December » December 2, 2010

Advinus and Corning Sign Agreement to Bring Corning® Epic® Technology to India

December 2, 2010 - New Delhi, Delhi, India

Advinus Therapeutics, the research-based pharmaceutical company promoted by the TATA Group, and Corning Incorporated (NYSE: GLW) today announced a collaboration to bring Corning® Epic® label-free detection technology to India.

The collaboration between Advinus and Corning enables Advinus to leverage the Corning Epic technology to enhance its own drug discovery capabilities and to provide assay development and screening services to companies both in India and abroad. “This collaboration is in line with Corning’s strategy of bringing innovative technology to India through collaborations with leading Indian companies”, said Rustom Desai, President, Corning India.

Corning Epic technology combines biochemical detection and cellular analysis on a single label-free platform to enable a better understanding of biological activity for a wide range of research applications. Corning’s technology helps accurately identify targets, pathways, and interactions, providing more biologically relevant data to the drug discovery process.

Commenting on the collaboration, Dr. Kasim Mookhtiar, the CSO of Advinus said, “This collaboration on Corning’s Epic technology emphasizes Advinus’ commitment to set up unique Pharma R & D services in India and to explore new and cutting-edge technologies to enhance our drug discovery capabilities. We are excited about the opportunities this will open for our customers and for our relationship with Corning in the area of enhanced drug discovery.”

"This collaboration highlights the growing adoption of label-free technology and the biological insights it enables in drug discovery research," said Ron Verkleeren, director, Advanced Life Sciences. "We believe this is an important step forward in making our Epic technology more accessible to life science researchers worldwide."

About Corning Incorporated ( )

Corning Incorporated ( is the world leader in specialty glass and ceramics. Drawing on more than 150 years of materials science and process engineering knowledge, Corning creates and makes keystone components that enable high-technology systems for consumer electronics, mobile emissions control, telecommunications and life sciences. Our products include glass substrates for LCD televisions, computer monitors and laptops; ceramic substrates and filters for mobile emission control systems; optical fiber, cable, hardware & equipment for telecommunications networks; optical biosensors for drug discovery; and other advanced optics and specialty glass solutions for a number of industries including semiconductor, aerospace, defense, astronomy and metrology.

About Advinus Therapeutics ( )

Advinus Therapeutics is a research-based Pharmaceutical Company founded by leading global pharmaceutical executives and promoted by the TATA Group. The company is the first of its kind in India to offer end-to-end development services to the global Pharma, Agro and Biotech industries and at the same time creating long-term value through internal and collaborative innovative Drug Discovery. Advinus Drug Discovery, located in a state of the art facility in Pune (near Mumbai), is developing its own drug candidates with the objective of out-licensing them at preclinical or clinical stages. The therapeutic areas of focus of these programs are in Metabolic Diseases, Inflammatory Diseases and neglected diseases such as Leishmaniasis. Advinus’ Pharmaceutical development operation is based out of Bangalore and is set on a 9-acre campus with 240,000 sq. ft of modern facilities. This center progresses our discovery compounds from Pune through pre-clinical development by performing all IND track studies and also by managing the early clinical development of these compounds. The Bangalore center additionally offers its capabilities of end-to-end pre-clinical to early clinical development as services for pharmaceutical product development. The services areas include Process Development, Drug Metabolism and Pharmacokinetics, Clinical Pharmacology, Safety Assessment and Analytical R&D. The Bangalore center is also one of the most accredited R&D centers of India with certification from AAALAC International and from the German, Dutch and Indian authorities for GLP compliance. In its management and senior leadership the team, the Company has over 150 years of drug discovery and drug development experience in U.S. large Pharmaceutical companies, with specific experience of handling dozens of IND and NDA filings.

Source: Business Wire India


Comment on this story